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An international case-control study of primary pediatric brain tumors included interviews with
mothers of cases diagnosed from 1976 to 1994 and mothers of population controls. Data are
available on maternal vitamin use during pregnancy for 1051 cases and 1919 controls from eight
geographic areas in North America, Europe, and Israel. Although risk estimates varied by study
center, combined results suggest that maternal supplementation for two trimesters may
decrease risk of brain tumor (odds ratio [OR] 0.7, 95% confidence interval [CIl 0.5-0.9), with a
trend of less risk with longer duration of use (p trend =0.0007). The greatest risk reduction was
among children diagnosed under 5 years of age whose mothers used supplements during all
three trimesters (OR 0.5, Cl 0.3-0.8). This effect did not vary by histology and was seen for
supplementation during pregnancy rather than during the month before pregnancy or while
breast feeding. These findings are largely driven by data from the United States, where most
mothers took vitamins. The proportion of control mothers who took vitamins during pregnancy
varied tremendously: from 3% in Israel and France, 21 % in Italy, 33% in Canada, 52% in Spain
and 86 to 92% at the three U.S. centers. The composition of the various multivitamin compounds
taken also varied: the daily dose of vitamin C ranged from 0 to 600 mg, vitamin E ranged from 0
to 70 mg, vitamin A ranged from 0 to 30,000 IU, and folate ranged from 0 to 2000 pg. Mothers
also took individual micronutrient supplements (e.g., vitamin C tablets), but most mothers who
took these also took multivitamins, making it impossible to determine potential independent
effects of these micronutrients. Environ Health Perspect 106(Suppl 3):887-892 (1998).
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Introduction
Brain tumors are a leading cause of cancer
deaths in children in developed countries
(1). Little is known about the causes of
these tumors (2). A family history of mul-
tiple nervous system tumors, which usually
occur in association with predisposing
genetic syndromes, appears to be a factor
in fewer than 5% of cases (3). Exposure to
X-rays and to other forms ofionizing radi-
ation is the only clearly established envi-
ronmental cause but accounts for only a
few percent of cases (4). Many other sug-
gested risk factors have been investigated
including head trauma, parental occupa-
tional exposures, medication use, and diet
(4). This paper looks at maternal use of
prenatal vitamin supplements.
An incidental finding in an early
case-control study of pediatric brain
tumors provided the first indication that
prenatal vitamin supplementation might be
related to reduced brain tumor risk (5). In
this study, mothers were asked about the
use ofseveral specific medications during
pregnancy; in answer to a final question
about any other drugs, more control moth-
ers than case mothers volunteered that they
had taken prenatal vitamins (odds ratio
[OR] 0.6) (5). More than a decade later,
several studies reported similarly decreased
risk related to maternal use ofprenatal vita-
mins. These include studies ofspecific his-
tologic subgroups of cases such as primitive
neuroectodermal tumors (PNET) (6) and
astrocytoma (2) and studies ofall types of
pediatric brain tumors combined (7). In
the largest study to date, decreased risk
related to prenatal vitamin supplementa-
tion was apparent for all types of tumors
combined as well as for each of the three
major subtypes (astroglial tumors, PNET,
and other glial tumors) (8). This paper
includes data from the Preston-Martin et
al. (8) study, which was the U.S. portion
of an international collaborative study of
childhood brain tumors, as well as data
from centers in France, Italy, Spain, Israel,
and Canada.
Methods
We investigated whether intake ofvitamin
supplements by the mother during preg-
nancy, during the month before preg-
nancy, or while breast feeding were related
to risk ofpediatric brain tumors, including
each ofthree major histologic subgroups of
these tumors. Dose-response relationships
were evaluated. The prevalence of vitamin
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intake across the countries in the study and
the micronutrient content ofsupplements
used were compared.
Subjects in this studyparticipated in the
international population-based case-control
study conducted to investigate risk factors
for primary brain tumors in children.
Investigators from nine centers (Paris,
France; Milan, Italy; Valencia, Spain; Israel;
Winnipeg, Canada; Los Angeles and San
Francisco, California; Seattle, Washington;
and Sydney, Australia) collaborated to
develop the international protocol, design a
standard questionnaire, and make decisions
regarding study conduct and analysis. This
study was coordinated by the International
Agency for Research on Cancer in Lyon,
France, where data from the centers were
compiled and merged into a combined data
set that indudes 1218 cases and 2223 con-
trols. Ofthese, maternal vitamin supple-
mentation datawere available for 1051 cases
(86%) and 1919 controls (86%). Analyses
excluded subjects forwhom vitamin supple-
mentation data were not collected (all
Sydney subjects and 35 cases [78%] and 58
controls [70%] from Winnipeg) and for
whom information on vitamin supple-
mentation was unknown (12 cases and 10
controls from Milan, Paris, andValencia).
Controls were frequency matched to
cases in all U.S. centers and in Paris; other-
wise they were individually matched.
Matching variables were sex, age, and at
five centers (Seattle, Winnipeg, Valencia,
Milan, and Israel), geographic region.
Cases were diagnosed during a range of
years from 1976 to 1994. In Israel, cases
were diagnosed between 1976 and 1992; in
Paris, 1985 and 1987; in Milan, 1984 and
1988; in Valencia, 1983 and 1990; in Los
Angeles, 1984 and 1991; and in Seattle
and San Francisco, 1984 and 1990. Diag-
nosis years in Winnipeg were between
1980 and 1994; however, questions con-
cerning maternal vitamin use were added
to that questionnaire only in the final years
ofthe study. The range ofage at diagnosis
covered birth to 19 years overall, with
some variation in the upper age by study
center. The maximum age included was 19
years in all U.S. centers and in Israel and
Winnipeg, 16 years in Milan, 15 years in
Paris, and 14 years in Valencia. A reference
age and reference date was defined for each
control. In the United States, this was the
age and date when the control reached the
age ofdiagnosis ofa similar case; in other
centers, this was the age ofthe control at
the time ofselection for the study and the
date ofselection. Approximately one-third
ofchildren with brain tumors for whom
vitamin supplement data were available was
younger than 5 years of age; 54% were
male, and 50% had astroglial tumors (Table
1). All cases that had a primary tumor ofthe
brain, cranial nerves, or cranial meninges
(International Classification ofDiseases-
Oncology [World Health Organization,
Geneva]) site codes 191, 192.1, and 192.2)
were eligible (8). Further details ofcontrol
selection and other study design features at
each of the participating centers are avail-
able from earlier reports from individual
centers (9-12).
The common study questionnaire
asked mothers about several exposures
they may have had during the index preg-
nancy, including use ofspecific medica-
tions. The final questions in this section of
the questionnaire asked about use ofvita-
min supplements. Mothers were asked
specifically about intake ofmultivitamins
and ofvitamin C and vitamin E supple-
ments. Detailed data were collected on
timing (month before pregnancy, specific
trimesters, use during breast feeding),
brand or type, frequency, and duration of
vitamin supplementation.
At some centers, vitamin use was not
queried in the standard manner. In Paris,
for example, a mother's use ofvitamin
supplements was queried in the section on
her diet during pregnancy; therefore, no
information is available on use during the
month before pregnancy or while breast
feeding. Each centerprovided micronutrient
content for eachsupplement brandreported.
Neither the U.S. centers nor Winnipeg had
information on the brand name ofsupple-
ments used; for U.S. centers, however, the
specific type ofmultivitamins taken was
queried (e.g., regular, high potency, prena-
tal). Where type but not specific brand of
vitamin was reported, market surveys were
conducted to determine average levels of
micronutrients in various types ofsupple-
ments. The percentage of respondents
from each center (other than the United
States and Winnipeg) who reported vita-
min use but did not report specific brands
was 72% in Israel, 67% in Milan, and 57%
in Valencia. Micronutrient analyses were
restricted tovitaminsC, E,A, andfolate.
Maximum likelihood estimates ofORs
and 95% confidence intervals (CIs) were
computed using both conditional and (to
minimize the problem of missing data
within strata) unconditional logistic regres-
sion stratified by center, sex, and age group
(13). Five centers (Seattle, Winnipeg,
Table 1. Characteristics ofcases and controlswith maternal vitamin supplementation data available; international







<5 372 35 579 30
5-9 315 30 594 31
10-14 227 22 448 23
15-19 137 13 298 16
Male 564 54 1068 56
Year of diagnosisa
1976-1979 3 0.3 6 0.3
1980-1984 167 16 270 14
1985-1989 685 65 1256 65
1990-1994 196 19 387 20
Morphologic subgroup
Astroglial 529 50
Primitive neuroectodermal 232 22
Otherglial 282 27 - -
Unknown 8 1 - -
Studycenter
Paris 67 6 107 6
Milan 80 8 314 16
Valencia 57 5 116 6
Israel 300 29 573 30
Winnipeg 14 1 21 1
LosAngeles 300 29 307 16
San Francisco 101 10 200 10
Seattle 132 13 281 15
&Varied by study center. For non-U.S. controls, age and year of diagnosis are the age and year of selection. For
U.S. controls, age and year are the age at diagnosis of a similar case and the year in which the control attained
the case's diagnosis age.
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Valencia, Milan, and Israel) also used
geographic region as a matching variable.
Unconditional risk estimates for Seattle
and Winnipeg were also adjusted for geo-
graphic region. For the other centers that
matched on region (Valencia, Milan, and
Israel), there were too many regional levels
to allow for adjustment in unconditional
analyses. For individually matched studies,
strata for conditional analyses were defined
by matched sets; for frequency matched
studies, strata were defined by center, sex,
and age group (0-1, 2-3, 4-5, 6-8, 9-11,
12-14, or 15-19 years of age). Because
estimates were similar using both condi-
tional and unconditional methods, only
results from unconditional analyses are
reported. Birth year, parents' education,
and child's use ofvitamin supplements
were considered potential confounders.
Parents' education was defined as the high-
est level attained by either parent and was
dichotomized for analysis; parents in the
upper level had at least some college educa-
tion. Race was not considered a con-
founder because ofits homogeneity within
each center except Los Angeles (race as a
potential confounder in the U.S. data is
addressed in "Discussion"). Risk estimates
and CIs from random effects models (with
center as the random effect) are reported
for exposure effects that differed by center
(14); otherwise, results from fixed effects
models are reported. Other factors consid-
ered as possible effect modifiers were gender,
birth year, and parents' education. For
tumor-specific analyses, cases within each
tumor group were compared to all controls.
Morphologicsubgroups were defined bythe
World Health Organization (8): astroglial
(9380-9384, 9400-9421, 9424-9442),
PNET (9470-9473, 9501), and all other
tumors (8000-8004, 8010, 8800, 8801,
8850, 8900-8910, 8940-8990, 9060-9085,
9150-9161, 9350-9364, 9390-9394, 9450,
9451, 9480, 9490, 9500, 9503-9505,
9530-9538, 9540-9570). A series ofanaly-
ses restricted to histologically confirmed
cases (91% oftotal) was performed. Length
oftime between pregnancy and interview
was evaluated as a potential source ofbias.
Multiple logistic regression was used to
assess independent effects ofmultiple expo-
sures. Dose-response trend tests for indi-
vidual micronutrient intake wereperformed
using log-transformed data; for categorical
analyses, unexposed mothers were the ref-
erence group and cut points were tertiles of
exposure among all exposed mothers.
Hypothesis testing was two-sided, with a
significance level of 0.05. Analyses were
performed using Epilog Plus statistical
software (Version 3.99, Epicenter
Software, Pasadena, CA).
Results
Reported use ofvitamins duringthe prenatal
period varied considerably by study center.
Among control mothers, reported use var-
ied from 3% in Israel and Paris to 86 to
92% at the three U.S. centers (Table 2).
Intermediate levels ofuse were reported by
control women from the other centers
(21% in Milan, 33% in Canada, and 47%
in Valencia). A significantly decreased risk
ofchildhood brain tumor associated with
any reported use ofvitamins during preg-
nancy was observed with the Los Angeles
data (OR 0.5, CI 0.3-0.8, adjusted for age
at diagnosis and gender). Decreased risks
that did not reach statistical significance
were observed in San Francisco, Valencia,
and Winnipeg. Statistically nonsignificant
elevations in risk were observed with data
from Israel and Paris, the studycenterswith
the lowest reported levels ofvitamin use.
The remaining two study centers, Milan
and Seattle, had riskestimates of1.0.
When data for all sites were combined,
the risk ofbrain tumor associated with any
maternal prenatal vitamin use was 0.8 (CI
0.6-1.0) adjusted for age, sex, and study
center; with center as a random effect, the
OR was 1.0 (CI 0.4-2.4), and when data
from U.S. centers were excluded the OR
was 1.1 (CI 0.7-1.5). Refinement of the
exposure period was attempted by comput-
ing risk estimates associated with maternal
vitamin use during the month prior to the
pregnancy (as a surrogate for use during
very early pregnancy), during the preg-
nancy, and during breast feeding immedi-
ately after the child's birth, with
simultaneous adjustment for any use dur-
ing all periods (Table 3). Mothers could be
in none, one, two, or all three of these
exposure groups. Results suggest that any
decreased risk may be restricted to vitamin
use during pregnancy (OR 0.7, CI
0.-1.0). Relative to women who did not
use vitamins during the index pregnancy,
decreased risks for childhood brain tumor
were observed for those who used vitamins
for two trimesters (OR0.7, CI 0.5-0.9), or
throughout all three trimesters (OR 0.6,
CI 0.5-0.8, p trend=0.0007, Table 3).
The suggested decreased risk ofchildhood
brain tumors with increasing duration of
vitamin use during pregnancy was seen for
Table 2. Risk of childhood brain tumor by maternal vitamin supplementation during pregnancy by study center;
international collaborative case-control studyofchildhood braintumors, 1976-1994.
Studycenter Cases, no. (%) Controls, no. (%) OR(95% Cl)a
Israel 9(3) 15(3) 1.2 (0.5, 2.7)
LosAngeles 229(76) 263(86) 0.5(0.3, 0.8)
Milan 17(21) 65(21) 1.0(0.5,1.9)
Paris 6(9) 3(3) 4.3(0.8, 22.2)
San Francisco 89(88) 183(92) 0.7(0.3, 1.5)
Seattle 116(88) 249(89) 1.0(0.5, 1.8)
Valencia 27(47) 45(52) 0.6(0.3, 1.4)
Winnipeg 3(27) 7 (33) 0.6(0.1, 2.8)
&Adjusted forsexand agegroup; Seattle and Winnipeg are also adjustedforgeographic region.
Table 3. Risk of childhood brain tumor by exposure period and duration of daily maternal vitamin supplementation
during pregnancy; international collaborative case-control studyofchildhood brain tumors, 1976-1994.
Cases, no.1%) Controls, no. (%) OR (95% Cl)a
Exposure period
Duringthe month prepregnancy 49(5) 66(3) 1.2(0.8, 1.8)
During pregnancy 496(47) 839(44) 0.7(0.6, 1.0)
While breastfeeding 202(19) 351 (18) 0.9(0.7, 1.2)
Trimester of exposure
first 410(42) 687(38) 1.0(0.7, 1.4)
Second 457 (46) 772(43) 0.8(0.5, 1.3)
Third 451 (46) 760(42) 0.9(0.6, 1.5)
Duration
Nevertookdaily 579(56) 1107(58) 1.0
Lessthan twotrimesters 83(8) 143(8) 0.8(0.6, 1.2)
Twotrimesters 174(17) 267(14) 0.7(0.5,0.9)
Allthreetrimesters 207(20) 389(20) 0.6(0.5,0.8)
"Adjusted for center, sex, and age group; for exposure period and trimester of exposure analyses, each exposure
period is also adjusted forthe othertwo.
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Table 4. Riskofchildhood brain tumor by duration ofdaily maternal vitamin supplementation during pregnancy by
morphologic subgroupa; international collaborative case-control study ofchildhood brain tumors, 1976-1994.
Duration Cases, no. (%) Controls, no. (%) OR (95% CI)b
Astroglial
Nevertookdaily 263(50) 1107(58) 1.0
Lessthan twotrimesters 43 (8) 144(8) 0.8(0.5, 1.3)
Two trimesters 108(21) 270(14) 0.8(0.6, 1.1)
All three trimesters 112 (21) 389(20) 0.6(0.4, 0.9)
PNET
Nevertookdaily 138(60) 1107(58) 1.0
Less than twotrimesters 19(8) 143(8) 0.8(0.5, 1.5)
Twotrimesters 25(11) 267(14) 0.4(0.2, 0.8)
All three trimesters 49(21) 389(20) 0.6(0.4, 1.1)
Otherglial
Nevertookdaily 171(62) 1107(58) 1.0
Less than twotrimesters 20(7) 143 (8) 0.7(0.4, 1.2)
Two trimesters 41 (15) 267(14) 0.6(0.4, 1.0)
All three trimesters 46(17) 389(20) 0.5(0.3, 0.9)
&All controls were used for each subsetofcases.bAdjusted forcenter, sex, and age group.
each ofthe three major morphologic tumor
subtypes: astroglial (p trend= 0.009),
PNET (p trend=0.05), and other glial (p
trend =0.01) (Table 4). This effect was
apparent among children ofall ages, but
was somewhat more marked among chil-
dren who were younger than 5 years ofage
at diagnosis (Figure 1). When data from
U.S. centers were excluded, there was no
trend relating duration ofuse to risk.
Because most mothers took multivita-
min compounds, it is difficult to determine
effects of individual micronutrients.
Nonetheless, among children who were
younger than 5 years ofage at diagnosis,
there is a suggestion ofa decreasing risk of
tumor with increasing daily dose ofeach of
four micronutrients when analyzed indi-
vidually (Table 5). In general, there is a
progressive reduction ofrisk across the four
levels ofexposure for each ofthe micronu-
trients (p trend=0.01, 0.004, 0.002, and
0.002 forvitamins C, E, A, and folate), but
1.5 + --Ages < 5years 1.4 U All ages
1.3 Cl, ages < 5years










Never <2trimesters 2trimesters 3trimesters
tookdaily
Duration of use
Figure 1. Duration of daily use of prenatal vitamins
and risk of childhood brain tumors for children younger
than 5 years of age at diagnosis compared to all chil-
dren; international collaborative case-control study of
childhood brain tumors, 1976-1994. Ages<5 years, p
trend=0.003. All ages, ptrend=0.0007.
some differences among the various micro-
nutrients are noteworthy. For vitamin C,
risk reduction is progressive across exposure
levels, and risk among those who took at
least 100 mg per day is 0.5 (CI 0.3-0.9).
Forvitamins EandAandforfolate, there is
a sharp reduction ofrisk among those who
took a small level ofdailysupplement com-
pared to those who took none. For vitamin
E, risk was similarly reduced (OR 0.5)
among those in the third (10.3-13.2 mg)
and fourth (213.3 mg) exposure levels of
daily use. The highest levels ofexposure
were 100 mg or more for vitamin C, 13.3
mg or more for vitamin E, 5000 IU or
more for vitamin A, and 400 jig or more
for folate. Average levels of nutrients
contained in supplements reported by each
center varied considerably across centers:
vitamin C from 67 to 203 mg/dose, vita-
min E from 8 to 46 mg/dose, vitamin A
from 3738 to 25,000 IU/dose, and folate
from 100 to 1250 pg/dose (Table 6).
Although parents' education was not a
confounder, reduced brain tumor risk from
matemalvitaminsupplementationwas some-
what more evident among children with
more highly educated parents. However,
results when education was dichotomized
generally were consistent with each other.
For example, results from dose-response
analyses ofthe four micronutrients strati-
fied by education level were essentially the
same. Risk estimates were unchanged after
adjusting for children's use ofvitamin sup-
plements. Among controls, prevalence of
vitamin supplement use during pregnancy
gradually increased over time, from 49% in
the birth years from 1965 to 1969 to 57%
for birth years 1985 and later, and risk esti-
mates were generally lower among subjects
born in 1980 or later (though birth yearwas
not aconfounder). Riskestimateswere simi-
lar foreach gender and also did notdifferby
histologic confirmation. Interview quality
was considered a potential source ofbias;
however, only 6.5% ofall interviews were
deemed questionable or unsatisfactory by
theinterviewer.
Discussion
Intake of vitamin supplements during
pregnancy was associated with an apparent
Table 5. Dose response for maternal selected micronutrient supplementation during pregnancy for subjects
youngerthan 5 years of age atdiagnosis; international collaborative case-control study ofchildhood brain tumors,
1976-1994.
Dailydosagea Cases, no. (%) Controls, no. (%( OR (95% Cl)b
Vitamin C, mg
0.0 176 (47) 277 (48) 1.0
>0.0<75.9 66(18) 70(12) 0.8(0.5, 1.5)
.75.9<100.0 38(10) 55(10) 0.6(0.3, 1.1)
.100.0 93(25) 177(31) 0.5(0.3, 0.9)
Vitamin E, mg
0.0 180(49) 279(48) 1.0
>0.0<10.3 68(18) 77(13) 0.6(0.3, 1.1)
.10.3<13.3 28(8) 44(8) 0.5(0.2, 1.0)
. 13.3 95(26) 176(31) 0.5(0.3, 0.8)
Vitamin A, IU
0 180(49) 277(48) 1.0
>0<3900 61(16) 77(13) 0.6(0.3, 1.0)
.3900<5000 33(9) 41 (7) 0.6(0.3, 1.2)
.5000 97(26) 181 (31) 0.4(0.2,0.8)
Folate, pg
0 180(49) 277(48) 1.0
>0<13 65(18) 78(14) 0.6(0.3, 1.1)
>13<400 34(9) 40(7) 0.6(0.3, 1.3)
.400 92(25) 179(31) 0.5(0.3,0.8)
aExposure categories are mutually exclusive. bAdjusted for center, sex, and age group. Risk estimates are not
adjusted for other micronutrients in the table.
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Table 6. International variation in micronutrient
content of vitamin supplements; international col-
laborative case-control study of childhood brain
tumors, 1976-1994.
Average micronutrient contenta
VitC, Vit E, VitA, Folate,
Center mg mg IU pg
Paris 325 20 25,000 250
Milan 128 46 14,300 100
Valencia 67 8 3738 333
Israel 162 40 5750 1250
Winnipegb 175 40 5000 400
United Statesc 203 23 4500 380
Vit, vitamin. &Of vitamin brands and types reported
that contain that micronutrient. bSpecific brands and
types not reported; micronutrient content based on typ-
ical vitamin for the geographical area. CLos Angeles,
San Francisco, and Seattle.
reduction ofrisk in earlier studies (2,5-7,9)
and in this largest case-control study of
childhood brain tumors to date. Risk reduc-
tion appeared to relate only to use during
pregnancyrather than use duringthe month
before pregnancy or during breast feeding,
and the greatest risk reduction was observed
when vitamins were taken during the entire
pregnancy. The reduction ofrisk was great-
est among children diagnosed at younger
ages (<5 years at diagnosis), but also was
seen amongolder children.
This international study has a number
oflimitations that must be considered. The
small number of cases in most centers
(< 100 cases in all but the U.S. and Israeli
studies) and the low prevalence ofvitamin
use in some geographic areas (e.g., 3%
among control mothers in Israel and
Paris) resulted in varied center-specific
risk estimates and combined risk estimates
that were dominated by findings in the
United States, where vitamins were taken
by the majority of mothers. In fact, the
non-U.S. data added only a 14% increase
in number of exposed cases and a 19%
increase in number ofexposed controls,
despite increases of 126 and 178% in total
numbers ofcases and controls, respectively.
This may suggest that the U.S. findings are
the result ofan unknown confounder, such
as quality ofprenatal care, that is related to
reduced brain tumor risk, or that vitamin
compounds in the United States differ in
ways that make them more effective in
reducing risk. Although supplements used
in all geographic areas contained at least
some of each of the four micronutrients,
average levels of nutrients contained in
supplements reported by each center varied
considerably across centers, as indicated in
Table 6.
There is a suggestion that an increasing
reduction in risk occurs with increasing
daily intake ofeach micronutrient evaluated
(vitamins C, E, A, and folate), but because
most mothers took a multivitamin com-
pound, intake ofthese four was highly cor-
related. In addition, specific brand names of
vitamins taken were not known or not
recorded for many mothers (though U.S.
centers asked about specific types ofmulti-
vitamins taken). As in any retrospective
case-control study, the possible influence of
recall bias is a concern. We did not have the
necessary data to perform a validation
analysis against medical records. However,
in studies ofchildhood cancer, recall bias is
usually associated with case mothers trying
harder than control mothers to remember
medication use and other exposures during
the index pregnancy. Ifsuch bias is present
in relation to an apparently protective expo-
sure such as vitamin use, it would have had
the effect of biasing our risk estimates
toward the null. Further, there is some evi-
dence to suggest that recall bias does not
exist in studies ofadverse reproductive out-
comes that use mothers as respondents
(15). Though the lower risk estimates we
observed for later birth years may be due to
increasing prevalence ofsupplementation
over time, they may also suggest nondiffer-
ential poor recall among mothers whose
pregnancies were in the distant past.
In the U.S. portion ofthe study, findings
relating to vitamin use remained after con-
trolling for all factors considered in the
pooled analysis, as well as the mother's
education, social class (an index consider-
ing education and occupation ofhead of
household), ethnicity (Latino, other white,
black, and other), and the mother's diet
during pregnancy (9). The U.S. data were
also evaluated with respect to whether
pregnancies were planned, which did not
confound the U.S. results. It is possible
that respondents differed from nonrespon-
dents in these factors or in the exposures
we studied (although participation rates at
the U.S. centers were 70% or higher), or
that controls targeted for participation
(through random-digit dialing) were not
representative ofthe population. However,
these potential biases are not quantifiable
in this study. We are processing the dietary
data from each center to allow a combined
analysis of micronutrient intake from diet
and supplements, which will be particu-
larly useful for centers in which prevalence
of supplementation was low (e.g., Israel
and France) and thus a minor contributor
to population intake of micronutrients.
The dietary analysis will also allow us to
examine the modifying effects ofsupple-
ment intake in relationship to other dietary
constituents such as nitrite from cured
meats (an important consideration because
both vitamins C and E are effective inhibi-
tors of nitrosation, as described below).
However, the dietary data from this study
have their own set oflimitations. The focus
of this study was investigation of the N-
nitroso hypothesis. Therefore, the question-
naire asked only about those 40 to 50 foods
that account for 90% ofpopulation intake
ofnitrite, nitrate, and vitamins C and E in
each geographic area understudy (16). The
list of foods queried varied considerably
across centers. In addition, these lists were
not designed to assess intake of most
micronutrients (e.g., folate and vitamin A)
or macronutrients (e.g., fat or animal pro-
tein). The Israel study is an exception, how-
ever, in that relatively complete dietary data
(i.e., not just foods most correlated with
intake of nitrite, nitrate, and vitamins C
and E) were collected.
Our data suggest an increasing use of
prenatal vitamin supplements over time,
which is inconsistent with the modest
increase in U.S. incidence ofpediatric brain
tumors over the past 20 years (17). How-
ever, increased incidence is likely due to the
simultaneous effects of several different
factors, such as improved diagnosis and pos-
sible secular changes in environmental expo-
sures that may increase risk. The effects of
these potential influences on pediatric brain
tumor incidence cannot be disentangled
when comparing the trends in incidence and
prevalence ofthis single exposure.
Nitritefrom cured meats is an important
precursor ofcarcinogenic N-nitroso com-
pounds commonly formed in the gut after
ingestion ofprecursor compounds (18,19).
One group ofthese compounds, the nitro-
soureas, causes nervous system tumors in
experimental animals (20-24). When expo-
sure is transplacental, only low doses ofpre-
cursors such as sodium nitrite and ethyl urea
in the food and drinking water ofthe preg-
nant rats are required for 100% tumor
induction in offspring. This effect can be
blocked if ascorbate (vitamin C) and/or
alpha-tocopherol (vitamin E) are added to
the dams' diet (25). In the U.S. portion of
this study, we found risk ofbrain tumors to
be substantially higher for children ofmoth-
ers who consumed above-average quantities
ofcured meats during their pregnancies and
did not take vitamins compared with those
who did (9). This synergism also was seen in
a small earlier study (7). Thehypothesis that
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childhood brain tumors relate to maternal
exposure to N-nitroso compounds during
the pregnancy was the primary focus ofthis
international study.
Various possible mechanisms have been
suggested by which vitamin and mineral
supplementation may reduce cancer risk
(26). Antioxidants (e.g., vitamins C and E)
can prevent oxidative damaige to DNA by
scavenging free radicals (27). Some micro-
nutrients such as vitamins A and D have a
role in cell differentiation and proliferation
(28). Supplementation may prevent defi-
ciencies, such as folic acid deficiency, that
may lead to malignant transformation of
normal cells by weakening chromosomal
structure and altering gene expression (29).
Presence of micronutrients in the gut or
bladder can prevent endogenous formation
of carcinogens (such as N-nitroso com-
pounds) or alter metabolism ofmutagens.
It is possible that the developing brain may
be more susceptible to some ofthese effects
because of the higher rate of brain cell
proliferation during gestation and early
childhood and the fetal brain's lower ability
to rid itselfofmutagenic compounds (30).
Our findings of a huge variation in
prevalence ofprenatal vitamin use and of
the content ofvitamin compounds across
countries may be of interest to clinicians
and public health workers. In addition, we
hope that our findings will stimulate investi-
gators to consider vitamin supplementation
in future epidemiologic studies ofchildhood
brain tumors and other pediatric cancers.
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